|
1
|
Creighton CJ, Morgan M, Gunaratne PH,
Wheeler DA, Gibbs RA, Robertson Gordon A, Chu A, Beroukhim R,
Cibulskis K, Signoretti S, et al: Cancer Genome Atlas Research
Network: Comprehensive molecular characterization of clear cell
renal cell carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Junker K, Ficarra V, Kwon ED, Leibovich
BC, Thompson RH and Oosterwijk E: Potential role of genetic markers
in the management of kidney cancer. Eur Urol. 63:333–340. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Silahtaroglu A and Stenvang J: MicroRNAs,
epigenetics and disease. Essays Biochem. 48:165–185. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ross SA and Davis CD: MicroRNA, nutrition,
and cancer prevention. Adv Nutr. 2:472–485. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nimmo RA and Slack FJ: An elegant miRror:
microRNAs in stem cells, developmental timing and cancer.
Chromosoma. 118:405–418. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Selaru FM, Olaru AV, Kan T, David S, Cheng
Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, et al: MicroRNA-21 is
overexpressed in human cholangiocarcinoma and regulates programmed
cell death 4 and tissue inhibitor of metalloproteinase 3.
Hepatology. 49:1595–1601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dillhoff M, Liu J, Frankel W, Croce C and
Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and
a potential predictor of survival. J Gastrointest Surg.
12:2171–2176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie Y, Todd NW, Liu Z, Zhan M, Fang H,
Peng H, Alattar M, Deepak J, Stass SA and Jiang F: Altered miRNA
expression in sputum for diagnosis of non-small cell lung cancer.
Lung Cancer. 67:170–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rossi L, Bonmassar E and Faraoni I:
Modification of miR gene expression pattern in human colon cancer
cells following exposure to 5-fluorouracil in vitro. Pharmacol Res.
56:248–253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Neely LA, Rieger-Christ KM, Neto BS,
Eroshkin A, Garver J, Patel S, Phung NA, McLaughlin S, Libertino
JA, Whitney D, et al: A microRNA expression ratio defining the
invasive phenotype in bladder tumors. Urol Oncol. 28:39–48. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lv L, Huang F, Mao H, Li M, Li X, Yang M
and Yu X: MicroRNA-21 is overexpressed in renal cell carcinoma. Int
J Biol Markers. 28:201–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Feber A, Xi L, Luketich JD, Pennathur A,
Landreneau RJ, Wu M, Swanson SJ, Godfrey TE and Litle VR: MicroRNA
expression profiles of esophageal cancer. J Thorac Cardiovasc Surg.
135:255–260; discussion 260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mo JS, Park HW and Guan KL: The Hippo
signaling pathway in stem cell biology and cancer. EMBO Rep.
15:642–656. 2014.PubMed/NCBI
|
|
16
|
Harvey K and Tapon N: The
Salvador-Warts-Hippo pathway - an emerging tumour-suppressor
network. Nat Rev Cancer. 7:182–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G
and Lu D: Promoter hypermethylation-mediated down-regulation of
LATS1 and LATS2 in human astrocytoma. Neurosci Res. 56:450–458.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takahashi Y, Miyoshi Y, Takahata C,
Irahara N, Taguchi T, Tamaki Y and Noguchi S: Down-regulation of
LATS1 and LATS2 mRNA expression by promoter hypermethylation and
its association with biologically aggressive phenotype in human
breast cancers. Clin Cancer Res. 11:1380–1385. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Steinmann K, Sandner A, Schagdarsurengin U
and Dammann RH: Frequent promoter hypermethylation of tumor-related
genes in head and neck squamous cell carcinoma. Oncol Rep.
22:1519–1526. 2009.PubMed/NCBI
|
|
20
|
Wierzbicki PM, Adrych K, Kartanowicz D,
Stanislawowski M, Kowalczyk A, Godlewski J, Skwierz-Bogdanska I,
Celinski K, Gach T, Kulig J, et al: Underexpression of LATS1 TSG in
colorectal cancer is associated with promoter hypermethylation.
World J Gastroenterol. 19:4363–4373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Visser S and Yang X: Identification of
LATS transcriptional targets in HeLa cells using whole human genome
oligonucleotide microarray. Gene. 449:22–29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou GX, Li XY, Zhang Q, Zhao K, Zhang CP,
Xue CH, Yang K and Tian ZB: Effects of the hippo signaling pathway
in human gastric cancer. Asian Pac J Cancer Prev. 14:5199–5205.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nishio M, Hamada K, Kawahara K, Sasaki M,
Noguchi F, Chiba S, Mizuno K, Suzuki SO, Dong Y, Tokuda M, et al:
Cancer susceptibility and embryonic lethality in Mob1a/1b
double-mutant mice. J Clin Invest. 122:4505–4518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao B, Li L, Wang L, Wang CY, Yu J and
Guan KL: Cell detachment activates the Hippo pathway via
cytoskeleton reorganization to induce anoikis. Genes Dev. 26:54–68.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen KH, He J, Wang DL, Cao JJ, Li MC,
Zhao XM, Sheng X, Li WB and Liu WJ: Effects of LATS1 gene
methylation on biological function in human renal cell carcinoma
and Hippo-YAP signaling pathway. J Third Mil Med Univ.
36:1249–1254. 2014.
|
|
26
|
Liu S, Song L, Zhang L, Zeng S and Gao F:
miR-21 modulates resistance of HR-HPV positive cervical cancer
cells to radiation through targeting LATS1. Biochem Biophys Res
Commun. 459:679–685. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Teteloshvili N, Smigielska-Czepiel K, Yuan
Y, Seitz A, de Jong D, Rutgers B, Jellema P, van der Lei RJ,
Slezak-Prochazka I, Brouwer E, et al: Argonaute 2
immunoprecipitation revealed large tumor suppressor kinase 1 as a
novel proapoptotic target of miR-21 in T cells. FEBS J.
284:555–567. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu S, Song L, Zhang L, Zeng S and Gao F:
miR-21 modulates resistance of HR-HPV positive cervical cancer
cells to radiation through targeting LATS1. Biochem Biophys Res
Commun. 459:679–685. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia H, Qi H, Li Y, Pei J, Barton J,
Blackstad M, Xu T and Tao W: LATS1 tumor suppressor regulates G2/M
transition and apoptosis. Oncogene. 21:1233–1241. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen J and Wang X: MicroRNA-21 in breast
cancer: Diagnostic and prognostic potential. Clin Transl Oncol.
16:225–233. 2014. View Article : Google Scholar : PubMed/NCBI
|
